Document:

EXHIBIT 10.68  FY2008 10K

Exhibit 10.68

AMENDMENT NO. 1

to

ASSIGNMENT AGREEMENT

This AMENDMENT TO ASSIGNMENT AGREEMENT
("Amendment"), effective as of May 12, 2008 (the
"Amendment Date"), is made and entered into by and between
PHARMACYCLICS, INC., a Delaware corporation having a place of business at
995 East Arques Avenue, Sunnyvale, California 94085,
("Pharmacyclics") and APPLERA CORPORATION, a Delaware
corporation, through its CELERA GROUP having a place of business at 45
West Gude Drive, Rockville, Maryland 20850 ("Celera").
Pharmacyclics and Celera may each be referred to herein individually as a
"Party" or, collectively, as "Parties."

WHEREAS, Pharmacyclics and Celera are parties to the
Assignment Agreement, effective as of April 7, 2006, whereby Celera assigned to
Pharmacyclics certain proprietary technology and know-how related to the Celera
Programs, including but not limited to the [***] (the "Assignment
Agreement");  

WHEREAS, Pharmacyclics desires that certain payment
terms of the Assignment Agreement relating to [***] be amended; and 

WHEREAS, Celera desires that such payment terms should
be amended, subject to the terms and conditions set forth below.  

NOW, THEREFORE, in consideration of the mutual
covenants and obligations set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged,
Pharmacyclics and Celera hereby agree as follows: 

	In General.  

All terms defined in the Assignment Agreement shall have a meaning in this
Amendment as in the Assignment Agreement, unless otherwise expressly defined in
this Amendment.  

	Amendment of the Assignment Agreement.

2.1   Amendment of Section 6.3.  Section 6.3 of the
Assignment Agreement is hereby amended to read in its entirety as follows;

6.3Product Milestones

(a)Pharmacyclics will pay to Celera payments as set
forth in this Section 6.3 within thirty (30) days after (i) under Section 6.3(b)
and 6.3(c), Pharmacyclics' receipt of upfront and milestone payments from one or
more Third Parties upon the grant by Pharmacyclics of a sublicense to such Third
Party under the Celera Technology and the Celera Patents to make, use, offer to
sell, sell and import any Assigned Product which is an

[***], and
(ii) under Section 6.3(d), the first achievement of the corresponding milestone
for an Assigned Product which is an [***] or which is a
[***].  Such payments shall be made in Dollars by wire transfer of
immediately available funds into an account designated by Celera.  No
achievement milestone payment will be payable more than once, no matter how many
times such milestone is achieved by a single Assigned Product or by multiple
Assigned Products in each of the [***] category or the
[***] category.  Such payments will be nonrefundable and
non-creditable against Royalties payable pursuant to Sections 6.4, and any other
fees, milestone payments or other payments due Celera under this
Agreement.

(b)Subject to the terms and conditions of this
Agreement, in the event that Pharmacyclics, within [***] of the
Amendment Date, grants a sublicense to one or more Third Parties under the
Celera Technology and the Celera Patents to make, use, offer to sell, sell and
import any Assigned Product which is an [***], Pharmacyclics will
pay to Celera the first [***] Dollars ($[***])
received by Pharmacyclics as upfront and milestone payments from such Third
Parties.  For purposes of this Section 6.3(b) and Section 6.3(c), the term
"upfront and milestone payments" does not include amounts reasonably
and fairly attributable to bona fide (i) debt financing, (ii) sale of equity in
Pharmacyclics, (iii) reimbursement for the cost and expense of research,
development and clinical services incurred by Pharmacyclics after the effective
date of such sublicense and attributable to [***], or (iv)
reimbursement of patent filing, prosecution and maintenance expenses incurred by
Pharmacyclics and attributable to [***].

(c)  Subject to the terms and conditions of this
Agreement, in the event that Pharmacyclics, at any time subsequent to
[***] after the Amendment Date, grants a sublicense to one or more
Third Parties under the Celera Technology and the Celera Patents to make, use,
offer to sell, sell and import any Assigned Product which is an
[***], Pharmacyclics will pay to Celera the greater of (i)
[***]% of the first $[***] received by Pharmacyclics
as upfront and milestone payments from such Third Parties, up to a total of
$[***] or (ii) [***]% of any Upfront Payments
received from such Third Party. The foregoing amounts will be determined as and
when Pharmacyclics receives such amounts and will take into account all payments
received by Pharmacyclics as described in this Section 6.3(c). For purposes of
this Section 6.3(c), the term "Upfront Payment" means any cash payment
that, under the terms of the relevant sublicense, is a firm and certain payment
obligation as of the effective date of such sublicense, but not including
amounts reasonably and fairly attributable to bona fide (i) debt financing, (ii)
sale of equity in Pharmacyclics, (iii) reimbursement for the cost and expense of
research, development and clinical services incurred by Pharmacyclics after the
effective date of such sublicense and attributable to [***], or
(iv) reimbursement of patent filing, prosecution and maintenance expenses
incurred by Pharmacyclics and attributable to

                                       2

[***], and is
independent of the achievement by Pharmacyclics of any performance
milestone.

For example: if Pharmacyclics has paid Celera
$[***] due to Celera from an initial Third Party sublicense agreement
through 6.3(c)(i), but then enters into a second Third Party sublicense
agreement where Pharmacyclics receives from such Third Party an Upfront Payment
of $[***], Pharmacyclics would pay Celera an additional $[***]
(calculated $[***] X [***]% = $[***], less $[***]
previously paid to Celera = $[***]). 

(d)Subject to the terms and conditions of this
Agreement, Pharmacyclics will pay Celera milestone payments in accordance with
the following table:

	
Milestone Event
	
Milestone Payment Amount (Dollars)

	 	
[***]
	
[***]

	1.[***]

	
$[***]
	
$[***]

	2.[***]

	
$[***]
	
$[***]

	3.[***]

	
$[***]
	
$[***]

	4.[***]

	
$[***]
	
$[***]

	5.[***]

	
$[***]
	
$[***]

	6.[***]

	
$[***]
	
$[***]

	7.[***]

	
$[***]
	
$[***]

	
	

	
Total
	
$[***]
	
$[***]

2.2 Amendment of Section 6.4.
Section 6.4 of the Assignment Agreement is hereby amended to read in its
entirety as follows;

6.4Royalties

(a)Subject to the terms
and conditions of this Agreement, Pharmacyclics will pay Celera a tiered Royalty
in accordance with the following table on worldwide Net Sales:

                                       3

	
Total Net Sales of an
Assigned Product in
a Calendar
Year
	
Percent of Net Sales 

	 	
[***]
	
[***]
	
[***]

	
[***] to $[***]
	
[***]%
	
[***]%
	
[***]%

	
$[***] to $[***]
	
[***]%
	
[***]%
	
[***]%

	
Above $[***]
	
[***]%
	
[***]%
	
[***]%

(b)Notwithstanding Section 6.4(a) as applied to
[***], subject to the terms and conditions of this Agreement, in
the event that Pharmacyclics, grants a sublicense to one or more Third Parties
under the Celera Technology and the Celera Patents to make, use, offer to sell,
sell and import any Assigned Product which is an [***],
Pharmacyclics will pay to Celera a Royalty with respect to sales of such
sublicensed [***] equal to the greater of (i) [***]
percent ([***]%) of any royalties on sales of such sublicensed
[***] received by Pharmacyclics from such Third Parties or (ii)
[***]% of worldwide Net Sales of such sublicensed
[***] sold by such Third Parties. In each case (i) and (ii) above,
no payments will be due or payable by Pharmacyclics to Celera under Section
6.4(a) with respect to sales of such sublicensed [***] by such
Third Parties.  For purposes of clarification, Pharmacyclics will pay to Celera
the Royalties set forth in Section 6.4(a) on Net Sales of such
[***] sold by or through Pharmacyclics, other than through the
above-described sublicenses.

(c)Pharmacyclics may deduct from Royalties payable
to Celera pursuant to Sections 6.4(a) and/or 6.4(b), as applicable, up to
[***] percent ([***]%) of any amounts paid to Third
Parties to obtain licenses or other rights under any Patents to the extent that,
without such licenses or rights, Pharmacyclics cannot otherwise make, use, sell,
offer for sale, or import the applicable Assigned Product without infringing a
claim of such Patent; provided that, after such deduction, the amount paid to
Celera is not less than [***] percent ([***]%) of
the amount that would otherwise have been paid to Celera pursuant to Sections
6.4(a) or 6.4(b), as applicable.  As a condition to benefiting from this Section
6.4(c), Pharmacyclics must deliver to Celera a true copy of each agreement with
a Third Party that Pharmacyclics contends is subject to this Section 6.4(c).
Each such agreement shall be treated by Celera as Pharmacyclics' Confidential
Information.

	Reference to and Effect on the Assignment Agreement.

3.1Pursuant to Section 13.1 of the Assignment
Agreement, this Amendment shall be effective upon the Amendment Date, whereupon
the Assignment Agreement shall be, and hereby is, amended as set forth
herein.

                                       4

3.2On and after the Amendment Date, each reference
in the Assignment Agreement to "this Agreement,"
"hereunder," "hereof," "herein" or words of like
import shall mean and be a reference to the Assignment Agreement as amended
hereby.  No reference to this Amendment need be made in any instrument or
document at any time referring to the Assignment Agreement, a reference to the
Assignment Agreement in any of such to be deemed to be a reference to the
Assignment Agreement as amended hereby.  

3.3All provisions of the Assignment Agreement not
expressly modified by this Amendment shall remain in full force and effect.

	Counterparts. 

This Amendment may be executed in one or more
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute a single instrument.

Signature Page Follows

*** Indicates that material has been omitted and confidential treatment
has been requested therefore all such omitted material has been filed separately
with the Commission pursuant to Rule 246-2.

                                       5

IN WITNESS THEREOF, the Parties have caused this
Amendment to be duly executed by their respective duly authorized officers as of
the Amendment Date.

	
PHARMACYCLICS, INC.

  ("Pharmacyclics")
	
APPLERA CORPORATION through its
CELERA GROUP

 ("Celera")

	
By:  /s/ RICHARD A. MILLER, M.D.
	
By:  /s/ VICTOR K. LEE, PH.D.

	
Print Name:  Richard A. Miller, M.D.
	
Print Name:  Victor K. Lee, Ph.D.

	
Title:  President & CEO
	
Title:  Assistant Secretary  

 

 

 

 

 

Signature Page to Amendment No. 1 to Assignment Agreement

                                       6EXHIBIT 10.69  FY2008 10K

Exhibit 10.69

PHARMACYCLICS, INC.

[DATE]

Dear _______:

The purpose of this amended and restated letter agreement
(this "Amended Letter Agreement") is to document the terms of
the severance package to which you will be entitled should there occur certain
changes in control of the Company or should your employment with Pharmacyclics,
Inc. (the "Company") be terminated involuntarily in connection
with such changes in control of the Company.

Part One of this Amended Letter Agreement specifies the terms
and conditions of your severance benefits. Part Two sets forth certain
definitional provisions to be in effect for purposes of determining your benefit
entitlements. Part Three concludes this agreement with a series of general terms
and conditions applicable to your benefits.

PART ONE - CHANGE IN CONTROL BENEFITS

Upon a Change in Control or any Change Related
Termination effected during the term of this Amended Letter Agreement, you will
become entitled to receive the special severance benefits set forth below.

	Severance Payments.  You will receive severance
payments from the Company following your Change Related Termination in an
aggregate amount equal to the sum of (A) one (1) times the annual rate of base
salary in effect for you at the time of your Change Related Termination plus (B)
one (1) times the average of the bonuses paid to you for services rendered in
the fiscal year immediately preceding the fiscal year of your Change Related
Termination. The severance payment will be paid to you in a lump sum on the date
of your Change Related Termination; provided, however, that, in
the event that you are considered by the Company to be a "Specified
Employee" as defined in proposed or final Treasury Regulations promulgated
under Section 409A ("Section 409A") of the Code, and payments
under this Paragraph 1 are considered non-qualified deferred compensation that
are subject to Section 409A, the payment shall be delayed until the earlier of
six months after your Change Related Termination or your death, in which event
you (or your estate) will receive on the first business day that is at least six
months and one day after the date of your Change Related Termination, or on the
first business day after the date of your death, if applicable, a lump sum equal
to all payments otherwise due pursuant to this Paragraph 1 through such
date.  All payments under this Paragraph 1 will be subject to the Company's
collection of applicable withholding taxes.

	Health Care Coverage.  The Company will, at its
expense, provide you and your eligible dependents with continued health care
coverage under the Company's medical/dental insurance plan until the
earlier of (i) one (1) year after the effective date of your Change
Related Termination or (ii) the first date that you are covered under another
employer's health benefit program which provides substantially the same level of
benefits without exclusion for pre-existing medical conditions. At the end of
such period, you will be entitled to continued health care coverage pursuant to
COBRA at your own expense to the extent permitted by law.

Page 2

	Option Acceleration and Vesting of Stock
Issuances.  Upon the occurrence of a Change in Control, as to all
outstanding Options then held by you which would otherwise become fully
exercisable or fully vest at least eighteen (18) months after the Change in
Control, the exercisability and vesting of such options shall be accelerated in
accordance with the following schedule: fifty percent (50%) of the previously
unexercisable or unvested portion immediately upon the Change in Control;
twenty-five percent (25%) of the portion unexercisable or unvested at the time
of the Change in Control one (1) year after the Change in Control (if you are
then still employed by the Company or its successor); and twenty-five percent
(25%) of the portion unexercisable or unvested at the time of the Change in
Control eighteen (18) months after a Change in Control (if you are then still
employed by the Company or its successor). All Options held by you at the time
of a Change in Control which will otherwise become fully exercisable or fully
vest within eighteen (18) months following the Change in Control will become
exercisable and vest in accordance with the following schedule: fifty percent
(50%) of the previously unexercisable or unvested portion immediately upon the
Change in Control; the remaining portion will continue to become exercisable and
vest in accordance with the exercise/vesting schedule applicable to those
Options at the time of the Change in Control. Similarly, as to all shares held
by you subject to a repurchase right in the Company which lapses over the course
of your employment at least eighteen (18) months after the Change in Control,
shall automatically vest, and the repurchase right with respect thereto shall
lapse, in accordance with the following schedule: fifty percent (50%) of the
shares subject to repurchase immediately upon the Change in Control; twenty-five
percent (25%) of the shares subject to repurchase one (1) year after the Change
in Control (if you are then still employed by the Company or its successor); and
twenty-five percent (25%) of the shares subject to repurchase eighteen (18)
months after the Change in Control (if you are then still employed by the
Company or its successor). Any shares subject to a repurchase right which
otherwise lapses within eighteen (18) months of the Change In Control will vest
(and the repurchase right will lapse) in accordance with the following schedule:
fifty percent (50%) of the shares subject to repurchase immediately upon the
Change in Control; the remaining shares will continue to vest (and the
repurchase right with respect to those shares will lapse) in accordance with the
vesting schedule otherwise applicable to those shares at the time of the Change
in Control.

In the event of any Change Related Termination during the
eighteen (18) month period after the Change in Control, all previously
unexercisable options (including options which did not accelerate at the time of
the Change in Control) shall become immediately exercisable and the repurchase
rights shall lapse as to all shares then held. Each such accelerated Option,
together with all of your other vested Options, will remain exercisable until
the earlier of (i) the expiration of the one (1)-year period measured from the
effective date of your Change Related Termination 

or (ii) the end of the specified ten (10)-year option term
and may be exercised for any or all of the option shares in accordance with the
exercise provisions of the option agreement evidencing the grant. In addition,
all of the unvested Stock Issuances you hold will (to the extent not then
otherwise vested) automatically vest upon your Change Related Termination.

	Benefit Reduction.  Should any of your severance
benefits under this Amended Letter Agreement be deemed to be parachute payments
under Code Section 280G, then the following limitations will become applicable:
(i) first, the dollar amount of your severance payment under Paragraph 1, and
(ii) then, the accelerated vesting of your options under Paragraph 3 will be
reduced to the extent (and only to the extent) necessary to provide you with the
maximum after-tax benefit available, after taking into account any parachute
excise tax

Page 3

which might otherwise be payable by you under Code Section 4999 and
any analogous State income tax provision.

	Restrictive Covenants.  For the twelve (12) month
period following your Change Related Termination:

	You will not directly or indirectly, whether for your own
account or as an employee, director, consultant or advisor, provide services to
any business enterprise which is at the time in competition with any of the
Company's then existing product lines and which is located geographically in an
area where the Company maintains substantial business activities, unless you
obtain the prior written consent of the Board.

	You will not directly or indirectly encourage or solicit
any individual to leave the Company's employ for any reason or interfere in any
other manner with the employment relationships at the time existing between the
Company and its current or prospective employees.

	You will not induce or attempt to induce any customer,
supplier, distributor, licensee or other business relation of the Company to
cease doing business with the Company or in any way interfere with the existing
business relationship between any such customer, supplier, distributor, licensee
or other business relation and the Company.

You acknowledge that monetary damages may not be sufficient
to compensate the Company for any economic loss which may be incurred by reason
of your breach of the foregoing restrictive covenants. Accordingly, in the event
of any such breach, the Company shall, in addition to the cessation of the
severance benefits provided you under this agreement and any remedies available
to the Company at law, be entitled to obtain equitable relief in the form of an
injunction precluding you from continuing to engage in such breach.

None of the foregoing restrictive covenants shall be
applicable in the event your Change Related Termination occurs in connection
with a Hostile Take-Over.

PART TWO - DEFINITIONS

Definitions.  For purposes of this Amended Letter
Agreement, the following definitions will be in effect:

Board means the Company's Board of Directors. Change
in Control means any of the following events:
(i)a merger or consolidation in which securities
possessing more than fifty percent (50%) of the total combined voting power of
the Company's outstanding securities are transferred to a person or persons
different from the persons holding those securities immediately prior to such
transaction and the composition of the Board of Directors of the Company
following such transaction is such that the directors of the Company prior to
the transaction constitute less than fifty percent (50%) of the Board membership
following the transaction,

Page 4

(ii)the sale, transfer or other disposition of all or
substantially all of the assets of the Company in complete liquidation or
dissolution of the Company, or

(iii)a Hostile Take-Over.

Change Related Termination means an Involuntary
Termination which occurs within thirty-six (36) months of a Change in
Control.

Code means the Internal Revenue Code of 1986, as
amended. Common Stock means the Company's common stock.

Health Care Coverage means the continued
medical/dental, vision and disability insurance coverage to which you and your
eligible dependents may become entitled under this agreement upon the Change
Related Termination of your employment other than Termination for Cause.

Hostile Take-Over means either of the following
events:
(i)the acquisition, directly or indirectly, by any person
or related group of persons (other than the Company or a person that directly or
indirectly controls, is controlled by, or is under common control with, the
Company) of beneficial ownership (within the meaning of Rule 13d-3 of the 1934
Act) of securities possessing more than fifty percent (50%) of the total
combined voting power of the Company's outstanding securities pursuant to a
tender offer made directly to the Company's stockholders which the Board does
not recommend such stockholders to accept, or

(ii)a change in the composition of the Board over a
period of thirty-six (36) consecutive months or less such that a majority of the
Board members ceases, by reason of one or more contested elections for Board
membership, to be comprised of individuals who either (A) have been Board
members continuously since the beginning of such period or (B) have been elected
or nominated for election as Board members during such period by at least a
majority of the Board members described in clause (A) who were still in office
at the time the Board approved such election or nomination.

Involuntary Termination means your "separation
from service" with the Company within the meaning of Section 409A:
(i)involuntarily upon your discharge or dismissal; or

(ii)voluntarily upon your resignation following (A) a
change in your position with the Company which materially reduces your level of
responsibility, (B) an annual compensation increase, if increases are given,
which is less than 50% of the mean increases given to all other corporate
officers, (C) a decrease in salary or compensation (health, benefits, vacation,
etc.) which is greater than ten percent (10%) above the decrease applicable to
other corporate officers on average, or (D) a relocation of your principal place
of employment by more than fifty (50) miles, provided and only if such change,
reduction or relocation is effected by the Company without your
consent.

In no event shall an Involuntary Termination be deemed to
occur should your employment terminate by reason of death or permanent
disability.

Page 5

1934 Act means the Securities Exchange Act of 1934, as
amended.

Option means any option granted to you under the
Company's 1992 Stock Option Plan, 1995 Stock Option Plan or any other equity
incentive plan subsequently adopted by the Company or any successor which is
outstanding at the time of your subsequent Change Related Termination.

Stock Issuance means the issuance of unvested shares
of Common Stock under the Company's 1992 Stock Option Plan, the 1995 Stock
Option Plan or any other equity incentive plan subsequently adopted by the
Company or any successor.

Termination for Cause means an Involuntary Termination
of your employment with the Company by reason of your commission of any act of
fraud, embezzlement or dishonesty, or your unauthorized use or disclosure of
confidential information or trade secrets of the Company or its subsidiaries or
your material failure to perform your duties as specified by the Chief Executive
Officer of the Company or the Board of Directors of the Company.

PART THREE - MISCELLANEOUS PROVISIONS

1.Termination for Cause.
Notwithstanding anything in this Amended Letter Agreement to the contrary,
should your Involuntary Termination constitute a Termination for Cause, then the
Company shall only be required to pay you (i) any unpaid compensation earned for
services previously rendered through the date of such termination and (ii) any
accrued but unpaid vacation benefits or sick days, and no benefits will be
payable to you under Part One of this Amended Letter Agreement.

2.Term of Agreement. The provisions of this
Amended Letter Agreement will continue in effect until [DATE]. Thereafter, this
Amended Letter Agreement will continue in effect from calendar year to calendar
year, unless terminated by written notice to you from the Company at least
thirty (30) days prior to the start of the next calendar year.  In the event of
a Change in Control, this agreement shall be automatically renewed for thirty-
six (36) months from the date of the Change in Control or until [DATE],
whichever is later.

3.General Creditor Status.  The benefits to which
you may become entitled under this Amended Letter Agreement (except those
attributable to your Options or Stock Issuances) will be paid, when due, from
the general assets of the Company. Your right (or the right of the executors or
administrators of your estate) to receive any such payments will at all times be
that of a general creditor of the Company and will have no priority over the
claims of other general creditors of the Company.

4.Death.  Should you die before receipt of all
benefits to which you become entitled under this Amended Letter Agreement, then
the payment of such benefits will be made, on the due date or dates hereunder
had you survived, to the executors or administrators of your estate. Should you
die before you exercise your Options, then each such Option may be exercised,
during the applicable exercise period in effect hereunder for those Options at
the time of your death, by the executors or administrators of your estate or by
person to whom the Option is transferred pursuant to your will or in accordance
with the laws of inheritance.

Page 6

5.Miscellaneous.  The provisions of this Amended
Letter Agreement will be construed and interpreted under the laws of the State
of California. This agreement incorporates the entire agreement between you and
the Company relating to the subject of severance benefits and supersedes all
prior agreements and understandings with respect to such subject matter. This
agreement may only be amended by written instrument signed by you and another
duly-authorized officer of the Company. If any provision of this Amended Letter
Agreement as applied to any party or to any circumstance should be adjudged by a
court of competent jurisdiction to be void or unenforceable for any reason, the
invalidity of that provision shall in no way affect (to the maximum extent
permissible by law) the application of such provision under circumstances
different from those adjudicated by the court, the application of any other
provision of this Amended Letter Agreement, or the enforceability or invalidity
of this Amended Letter Agreement as a whole. Should any provision of this
Amended Letter Agreement become or be deemed invalid, illegal or unenforceable
in any jurisdiction by reason of the scope, extent or duration of its coverage,
then such provision shall be deemed amended to the extent necessary to conform
to applicable law so as to be valid and enforceable or, if such provision cannot
be so amended without materially altering the intention of the parties, then
such provision shall be stricken and the remainder of this Amended Letter
Agreement shall continue in full force and effect.

6.Remedies. All rights and remedies provided
pursuant to this Amended Letter Agreement or by law will be cumulative, and no
such right or remedy will be exclusive of any other. A party may pursue any one
or more rights or remedies hereunder or may seek damages or specific performance
in the event of another party's breach hereunder or may pursue any other remedy
by law or equity, whether or not stated in this Amended Letter Agreement.

7.Arbitration.  Any controversy which may arise
between you and the Company with respect to the construction, interpretation or
application of any of the terms, provisions or conditions of this agreement or
any monetary claim arising from or relating to this agreement will be submitted
to final and binding arbitration in San Jose, California in accordance with the
rules of the American Arbitration Association then in effect.

8.No Employment or Service Contract.  Nothing in
this agreement shall confer upon you any right to continue in the employment of
the Company for any period of specific duration or interfere with or otherwise
restrict in any way the rights of the Company or you, which rights are hereby
expressly reserved by each, to terminate your employment at any time for any
reason whatsoever, with or without cause.

9.Proprietary Information.  You hereby acknowledge
that the Company may, from time to time during your employment with the Company,
disclose to you confidential information pertaining to the Company's business
and affairs. All information and data, whether or not in writing, of a private
or confidential nature concerning the business or financial affairs of the
Company (collectively, "Proprietary Information") is and will remain
the sole and exclusive property of the Company. In connection with such
Proprietary Information, you agree as follows:
(i)You will not, during your employment with the Company
or at any time thereafter, disclose to any third party or directly or indirectly
make use of any such Proprietary Information other than in connection with, and
in furtherance of, the Company's business and affairs.

Page 7

(ii)You agree that you will use all files, letters,
memoranda, reports, records, data or other written, reproduced or other tangible
manifestations of the Proprietary Information, whether created by you or others,
to which you have access during your employment with the Company, only in the
performance of your duties with the Company. You will return all such materials
(whether written, printed or otherwise reproduced or recorded) to the Company
immediately upon the termination of your employment with the Company or upon any
earlier request by the Company, without retaining any copies, notes or excerpts
thereof.

(iii)Your obligations under this Paragraph 9 will
continue in effect after the termination of your employment with the Company,
whatever the reason or reasons for such termination, and the Company will have
the right to communicate with any future or prospective employer concerning your
continuing obligations under this Paragraph 9.

Please indicate your acceptance of the foregoing provisions
of this severance agreement by signing the enclosed copy of this Amended Letter
Agreement and returning it to the Company.
PHARMACYCLICS, INC.

 

By:________________________

[●]

Title:[●]

 

 

Page 8

ACCEPTED BY AND AGREED TO

Signature:______________________

Dated:  [●]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]